SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In a clinical study, empagliflozin (SGLT-2 inhibitor) significantly reduced hepatic fat content in patients with type 2 diabetes and NAFLD (Kuchay et al., 2018).